Publications by authors named "Lisa Do"

The incidence of type 2 diabetes mellitus (T2DM) has increased in our society in recent decades as the population ages, and this trend is not expected to revert. This is the same for the incidence of the main neurodegenerative disorders, including the two most common ones, which are, Alzheimer's and Parkinson's disease. Currently, no pharmacological therapies have been developed to revert or cure any of these pathologies.

View Article and Find Full Text PDF

Patients with Post-COVID syndrome (PCS) are frequently referred for cardiologic evaluation. We assessed cardiac function and biomarkers in relation to functional status and fatigue in patients with PCS. This prospective single-center cohort study included 227 patients with persisting symptoms after COVID-19 infection.

View Article and Find Full Text PDF
Article Synopsis
  • Thrombocytopenia is a frequent side effect in cancer patients receiving antibody-drug conjugates (ADCs) such as AGS-16C3F and trastuzumab emtansine (T-DM1).
  • The study found that AGS-16C3F and T-DM1 do not directly impact platelets, but they inhibit the differentiation of megakaryocytes (MKs) through their active metabolites.
  • The research indicates that the reduction in MK differentiation and subsequent thrombocytopenia may be related to macropinocytosis, a process that assists in the internalization of AGS-16C3F into MKs.
View Article and Find Full Text PDF

MVA-BN®-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN®-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary metastasis. This anti-tumor efficacy occurred despite a strong tumor-mediated immunosuppressive environment characterized by a high frequency of regulatory T cells (T(reg)) in the lungs of tumor-bearing mice.

View Article and Find Full Text PDF

MVA-BN-PRO (BN ImmunoTherapeutics) is a candidate immunotherapy product for the treatment of prostate cancer. It encodes 2 tumor-associated antigens, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP), and is derived from the highly attenuated modified vaccinia Ankara (MVA) virus stock known as MVA-BN. Past work has shown that the immunogenicity of antigens can be improved by targeting their localization to exosomes, which are small, 50- to 100-nm diameter vesicles secreted by most cell types.

View Article and Find Full Text PDF